Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Covid

    Current Location

    Search
    Covid
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    Top COVID-19 Clinical Trials

    Top Leiomyosarcoma Clinical Trials near Long Beach, CA

    161 Clinical Trials near Arizona

    139 Clinical Paid Trials near Honolulu, HI

    183 Clinical Paid Trials near West Virginia

    181 Clinical Paid Trials near Omaha, NE

    188 Clinical Trials near Annapolis, MD

    Top Bronchiolitis Clinical Trials

    Top Cholesterol Clinical Trials

    Top Insomnia Clinical Trials

    Top Thrombocytopenia Clinical Trials

    Top Constipation Clinical Trials

    By Trial

    COVID Prevention Counseling and Text Messaging for COVID-19

    Paxlovid for COVID-19

    Molnupiravir for COVID-19

    Monitoring Heart Injury After COVID-19 Vaccination

    Antiviral Drugs for Long COVID

    Nutritional Supplement for COVID-19 Vaccine Side Effects

    Attention Training for Long COVID

    Structured Pacing for Long COVID

    V/Q System for Acute Respiratory Distress Syndrome in COVID-19

    Communal Drumming for Mental Health During COVID-19

    Preventive Behavioral Health Intervention for Pandemic-Affected Children

    Healthy ReStart Program for Mental Illness

    Related Searches

    Top Clinical Trials near Albuquerque, NM

    Top Abdominal-aortic-aneurysm Clinical Trials

    Icatibant for Low Blood Pressure During Dialysis

    Accelerated TMS for Hand Dystonia

    Medications for Cerebral Blood Flow Regulation

    Mobile Tech & Peer Health Coaching for Pregnant Black Teens

    Top Clinical Trials near Keesler Air Force Base, MS

    Top Metabolic-syndrome Clinical Trials

    Calcitriol for Hypophosphatemic Rickets

    Triple Drug Combo for Breast Cancer

    Antioxidant Exercise Training for Mental Illness

    Venetoclax + ASTX727 for Chronic Myelomonocytic Leukemia

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Clear All

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      87 Covid Trials Near You

      Power is an online platform that helps thousands of Covid patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      mRNA Vaccines Comparison for COVID-19 Prevention

      Reston, Virginia
      This trial is testing a new COVID-19 vaccine called mRNA-1283.222. It aims to see if this new vaccine is safe and effective. The vaccine works by using a small piece of genetic material to help the body recognize and fight the virus.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      14246 Participants Needed

      CVXGA Vaccine for Coronavirus

      Rockville, Maryland
      The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Acute Illness, Positive COVID-19, Autoimmune, Others
      Must Not Be Taking:Intranasal Medications, Immunosuppressants

      10016 Participants Needed

      Oral Vaccine for COVID-19

      Rockville, Maryland
      The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune, Immunodeficiency, Cancer, Others
      Must Not Be Taking:Antibiotics, Antacids, NSAIDs, Others

      10400 Participants Needed

      mRNA-1083 Vaccine for Influenza and COVID-19

      Rockville, Maryland
      The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Unstable Conditions, Recent Influenza, Others
      Must Not Be Taking:Immunosuppressants, Vaccines

      1300 Participants Needed

      PET Imaging for Post-COVID Syndrome

      Bethesda, Maryland
      Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from COVID-19 have long-term symptoms that affect the brain. These include headaches; loss of taste and smell; sleep problems; thinking problems; depression; and anxiety. Researchers want to know if a tracer (a substance that is injected into a person s body before an imaging scan) can help identify inflammation in people with these brain disorders. Objective: To see if a radioactive tracer (\[11C\]PS13) can highlight brain inflammation in those who had COVID-19 but still have symptoms that affect the brain. Eligibility: Adults aged 18 to 70 years with post COVID-19 brain disorders who are enrolled in protocol 000089 or 000711. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits. Participants will be screened. They will have blood tests and a test of their heart function. They will have imaging scans: Magnetic resonance imaging (MRI): They will lie on a table that slides into a metal tube. Pictures will be taken of the brain. Positron emission tomography (PET): A needle attached to a thin tube will be inserted into a vein in the arm. The tracer will be injected through the tube. Another needle attached to a thin tube will be inserted into the wrist or inside of the elbow of the other arm to draw blood. They will lie still on a bed while a machine captures images of their brain. The scan will last about 2 hours. Study involvement is 11 to 14 weeks....
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Unstable Medical Condition, Pregnancy, HIV, Others
      Must Not Be Taking:NSAIDs, Aspirin, Corticosteroids, Immunosuppressants

      60 Participants Needed

      mRNA-1273.214 Vaccine for COVID-19 in Children

      Burke, Virginia
      This trial tests updated COVID-19 vaccines on young children. The vaccines use mRNA to teach the body to recognize and fight the virus. The study aims to ensure these vaccines are safe and effective for this age group.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 5

      Key Eligibility Criteria

      Disqualifiers:SARS-CoV-2 Infection, Immunodeficiency, Others
      Must Not Be Taking:Immunosuppressants, Monoclonal Antibodies

      1860 Participants Needed

      Various Treatments for Long COVID

      Bethesda, Maryland
      Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms. The symptoms of long COVID can include extreme tiredness (fatigue), shortness of breath, memory and concentration issues (brain fog), heart palpitations, dizziness, joint pain, muscle aches, cough, headaches, anxiety, and depression. It's important to note that there are various other symptoms that individuals can experience after a COVID-19 infection, such as loss of smell, chest pain or tightness, difficulty sleeping (insomnia), pins and needles, depression, anxiety, tinnitus, earaches, nausea, diarrhea, stomach aches, loss of appetite, cough, headaches, sore throat, and changes to the sense of smell or taste. To be included in the study, participants must have had symptoms for more than 4 weeks. The goal of the study is to measure biomarkers, identify new ones through clinical trials, and individualize and optimize treatment plans, which may or may not include COVID-19 post-market antivirals, vaccines, and medical care. It's essential to conduct thorough clinical trials to understand the long-term effects of COVID-19 and to develop personalized treatment plans for individuals experiencing long-haul symptoms.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Myocarditis, Pericarditis, Severe Renal Impairment

      100 Participants Needed

      Medical Herbs for COVID-19

      Rockville, Maryland
      The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning. Once compromised by inflammation, the immune system loses its capacity to recognize antigens and dependably defend the body against disease and illness. When COVID-19 invades humans, it causes an immune-storm (cytokine-storm) that can directly damage the organ(s), leading to death. The virus is an antigen - a trigger - but it is not the actual reason that causes organ failure and death; instead, it is the body's over immune reaction that is the cause. In attempting to protect the body, the immune system overreacts to the antigen, which includes the infected cells, which causes a cytokine-storm, and the subsequent and rapid shut down of the infected individual's organ(s)' structure, leaving the body without sufficient strength or time to fight back. When the medical herbs join the body, it can slow down the immune reaction. Medical herbs benefit the physical body; they protect the cells and organism structure and mediate the immune response, allowing the T cells to kill the virus (mutated or not) internally. Such success has been achieved by the All Natural Medicine Clinic during pre-clinical trials. This clinical study's goal is to demonstrate that the immune system can be rebuilt and retrained, using natural medicine (i.e., medical herbs), to kill the virus without causing the immune storm, and to explore the mechanism by which these medical herbs, which have been used for thousands of years for healing, achieve results.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:10 - 70

      Key Eligibility Criteria

      Disqualifiers:Prior COVID-19, Age, Severe Illness, Others

      100 Participants Needed

      mRNA-1273.214 Vaccine for Infant COVID-19

      Burke, Virginia
      This trial will test a new COVID-19 vaccine in young infants to ensure it is safe and effective. The vaccine works by using mRNA to teach the body to fight the virus.

      Trial Details

      Trial Status:Active Not Recruiting
      Age:2 - 6

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      700 Participants Needed

      Shionogi Protease Inhibitor for COVID-19

      Bethesda, Maryland
      This trial will test a new medicine called ensitrelvir to help hospitalized COVID-19 patients by stopping the virus from multiplying.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Hepatic Impairment, Renal Failure, Pregnancy, Others
      Must Not Be Taking:Strong CYP3A Inducers

      1500 Participants Needed

      COVID-19 Vaccine for Children

      Washington, District of Columbia
      The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. * Substudy A design: Phase 1 includes participants 6 months through less than 4 years 3 months of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naïve) and will receive 3 doses of study vaccine as their initial series, followed by a fourth dose of study vaccine. Phase 2/3 includes participants 6 months through less than 5 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive 1, 2, or 3 doses of study vaccine, depending on what group they are in. * Substudy B design: includes participants 6 months through less than 5 years of age who have either received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy C design: Phase 1 includes participants 6 months through less than 5 years of age who have received 3 prior doses of BNT162b2 and will receive study vaccine as their fourth dose. * Substudy D design: includes participants 5 through less than12 years of age who have received 2 or 3 prior doses of BNT162b2 and will receive study vaccine as their third or fourth dose. * Substudy E design: includes participants 2 through less than 12 years of age who have not received a previous coronavirus vaccination (COVID-19 vaccine naive) and will receive a single dose of study vaccine.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:6 - 11

      Key Eligibility Criteria

      Disqualifiers:MIS-C, Autoimmune Disease, Myocarditis, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      3692 Participants Needed

      Exercise for COVID-19 Recovery

      Bethesda, Maryland
      Background: People who are recovering from COVID-19 may continue to have problems that affect their daily life. For instance, they might feel overly tired. Researchers want to learn if exercise can help people recover after COVID-19 infection. Objective: To study if participation in a rehabilitation exercise program can help people recovering from COVID-19. Eligibility: Adults ages 18-80 with a lab-confirmed SARS-CoV2 infection (the virus that causes COVID-19), and are still having some symptoms. Design: Participants will have a medical history and physical exam. They will give blood and urine samples. They will have tests to measure heart and lung function. Their blood vessels will be assessed. Participants will have a computed tomography scan of the body. They will have an ultrasound of the muscles in their arms, legs, and chest. Participants will take a 6-minute walk test. They will take other balance and movement tests. Participants will walk on a treadmill while hooked up to a monitor. Then they will be interviewed. It will be audio-recorded. Participants will complete surveys about their symptoms and daily activities. Participants will take a smell test. For this, they will identify different smells. They will also have memory, attention, and mental functioning tests. Participants will wear an activity monitor on their wrist 24 hours a day. They will exercise 3 times a week for 10 weeks by moving vigorously on a track or treadmill for 30 minutes. They will attend education classes once a week for 10 weeks. Participants will be contacted by phone or email every 3 months for 1 year after they complete the exercise part of the study. They will wear an activity monitor for up to 2 weeks.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Heart Disease, Cancer, Stroke, Diabetes, Others
      Must Not Be Taking:Beta Blockers, Antiretrovirals

      48 Participants Needed

      Various Treatments for Critically Ill COVID-19 Patients

      Washington, District of Columbia
      The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Liver Disease, Kidney Disease, Others

      1500 Participants Needed

      COVID-19 Therapeutic Biologic for COVID-19

      North Bethesda, Maryland
      Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19 patients with controlled cancers. 1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains. 2. Activate Human Antigen Presentation Reaction to COVID-19 Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process COVID-19 target antigen protein into small peptide fragments, and then COVID-19 virus can be killed by APCs directly.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Early Phase 1
      Age:24 - 64

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Cancers, Pregnancy, Others

      20 Participants Needed

      Novel Antibody Prophylaxis for COVID-19

      Annandale, Virginia
      This trial is testing a new drug, AZD3152, and a combination drug to see if they can prevent COVID-19. It focuses on people with weak immune systems who might not respond well to vaccines, as well as healthy adults. The drug works by blocking the virus from entering cells.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      3882 Participants Needed

      Noninvasive Biosensing Device for Respiratory Diseases

      Bethesda, Maryland
      Background: The COVID-19 outbreak has strained the health care system. New tools are needed for diagnostic testing and monitoring of people who have the virus. Researchers want to test a device they hope can screen, detect, and monitor symptoms linked to respiratory diseases like COVID-19. Objective: To evaluate and validate a device that measures breathing, body temperature, heart rate, and tissue oxygenation. Eligibility: Healthy adults ages 18 and older with no flu-like symptoms and no current signs of infection, cough, fever, or sneezing. Design: Participants will have a physical exam. Their vital signs will be taken. Participants will sit in a chair. They will be monitored for 60 to 80 minutes while they do the following tasks: Rest for 10 minutes. They will repeat this after each task. Hold their breath for up to 2 minutes and then rest for 2 minutes. They will do this task 3 times. Pace-breathe with breathing rates of 10, 20, and 30 breaths per minute. They will do this task 2 times. Breathe air that has 5% of carbon dioxide for 5 minutes. During these tasks, data will be collected and recorded with a pulse oximeter, thermometer, respiratory belt, and spirometer. Participants will fill out questionnaires related to their daily activity (medication intake, exercise, smoking, and drinking). Participation will last for 2 to 3 hours.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular, Pulmonary, Seizure, Smokers, Others
      Must Not Be Taking:Nitrates, Sulfonamides, Narcotics, Others

      40 Participants Needed

      Motor Memory Assessment for Post-COVID Syndrome

      Bethesda, Maryland
      Background: Most people who get COVID-19 seem to recover with no long-term effects. However, some people who recover from acute COVID-19 infections report lingering symptoms. This is called long COVID. Many people with long COVID report symptoms related to the nervous system; these can include problems with fatigue, speech, and memory. Objective: To test motor memory in people with long COVID, compared to healthy volunteers. Eligibility: People aged 18 to 90 years who are also enrolled in study protocol 000089. Healthy adults are also needed. Design: Participants will be screened by telephone. They will confirm they are able to type without discomfort using their nondominant hand. They will confirm they have access to a computer connected to the internet. All study tasks will be done online. Participants will complete 2 tasks in 2 days. Participants will be sent a link to a website. The website will give them instructions. They will place the fingers of their nondominant hand over 4 numbers on the keyboard and type a sequence (eg, 4-1-3-2-4). They will type this sequence as often as they can in 10 seconds. Then they will rest for 10 seconds before repeating the task. They will repeat this pattern for 15 minutes. After they finish the typing task, participants will take a 10-minute questionnaire. They will answer questions about their experiences with COVID-19 and memory issues; they will say which hand they use for tasks such as brushing their teeth or throwing a ball. Participants will get a notice to repeat the typing task 22 hours after they finish the first one. They should complete the second task within 28 hours....
      No Placebo Group

      Trial Details

      Trial Status:Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      1000 Participants Needed

      Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome

      Silver Spring, Maryland
      This trial tests a new treatment where tiny particles from bone marrow cells are used to help patients with severe lung problems by reducing inflammation and repairing lung damage.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Malignancy, Major Trauma, Others
      Must Not Be Taking:Investigational Agents

      970 Participants Needed

      Immunotherapy for Long-Haul COVID

      Bethesda, Maryland
      Background: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way. Researchers want to see if a treatment can help with people who have recovered from COVID-19 but still have symptoms ("Long COVID"). Objective: To learn if human immunoglobulin (IVIG) will help with neurological symptoms of Long COVID. Eligibility: Adults ages 18 and older who had COVID-19 at least 12 weeks ago and have ongoing neurologic symptoms, such as dizziness, trouble walking, or problems with strength. Design: Participants will be screened with a medical record review. Participants will have a medical history and a physical exam and complete questionnaires about their health and quality of life. They will have a spinal tap. They will give blood samples. They will discuss their symptoms with a neurologist and have a neurological exam. Participants will take memory and thinking tests using a tablet. The tests will take 1 hour to complete. They will also take a smell and taste test. It will take approximately 30 minutes to complete. Participants will lie on a table that tilts for up to 40 minutes. Their blood pressure and heart rate will be monitored. Blood will be taken through an intravenous (IV) catheter. Participants will receive either IVIG, or saline by IV for 5 days. Then the participants will receive IVIG if they first received saline or saline if they first received IVIG by IV for another 5 days. They will not know what they receive. Participants will have an MRI of the brain if they have not had one recently. They will receive a contrast agent by IV as part of the MRI scan. Participants will be on the study for up to 4 months. They will have follow-up visits at the clinical center as well as fill out questionnaires at home. They may be asked to continue follow-up....

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Traumatic Brain Injury, Substance Use, Others
      Must Not Be Taking:Oral Steroids, Immunosuppressives

      45 Participants Needed

      Tozorakimab for Viral Pneumonia

      Silver Spring, Maryland
      This trial is testing tozorakimab, a medication that may help people with severe viral lung infections who need extra oxygen. The goal is to see if it can prevent death or the need for advanced breathing support. Tozorakimab works by reducing harmful inflammation in the lungs.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:18 - 18

      Key Eligibility Criteria

      Disqualifiers:Fungal Infection, Parasitic Infection, Others

      2870 Participants Needed

      Why Other Patients Applied

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78
      Match to a Covid Trial

      Nature-Based + Virtual Mindfulness for Stress in Healthcare Workers

      Bethesda, Maryland
      This trial aims to reduce stress in healthcare workers treating COVID-19 patients by combining outdoor activities with online mindfulness exercises. The goal is to see if this combination is more effective than either approach alone.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Acute Psychiatric Condition, Hearing Impairment

      90 Participants Needed

      NE3107 for Post-COVID Syndrome

      Silver Spring, Maryland
      Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 64

      Key Eligibility Criteria

      Disqualifiers:Recent Vaccination, ICU Admission, Major Illness

      208 Participants Needed

      Sleep Treatments for Long COVID Syndrome

      Washington, District of Columbia
      The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Untreated Sleep Apnea, Narcolepsy, Others

      1074 Participants Needed

      Ivabradine and IVIG for Long COVID Syndrome

      Washington, District of Columbia
      This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Renal Failure, Atrial Fibrillation, Others

      380 Participants Needed

      Nasal Spray Vaccine for COVID-19

      Baltimore, Maryland
      This trial tests a new nasal spray vaccine on about 30 healthy volunteers. The vaccine uses a weakened virus to help the body recognize and fight COVID-19. Volunteers will be monitored for a long period after receiving the vaccine.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1
      Age:18 - 50

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Asthma, HIV, Hepatitis, Others
      Must Not Be Taking:Steroids, Immunosuppressants, Intranasal Medications

      27 Participants Needed

      T Cell Therapy for COVID-19

      Washington, District of Columbia
      This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell transplantation (HSCT). Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after HSCT). In this dose escalation trial, three doses (1x107/m2, 2x107/m2, and 4x107/m2) will be tested for safety, with study arms for adult (≥18 years of age and \<80 years) HSCT recipients (Arm A) and pediatric (≥12 years of age and \<18 years) HSCT recipients (Arm B), and defined dose escalations in each study arm. The study agent will be assessed for safety (stopping rules defined) and antiviral activity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:12 - 80

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Hypertension, Pulmonary Disease, Others
      Must Not Be Taking:Monoclonal Antibodies, JAK Inhibitors

      24 Participants Needed

      Home-Based Exercise for Post-COVID Fatigue

      Washington, District of Columbia
      The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population. The central hypothesis is that declines in force capacity, skeletal muscle oxygen extraction, and affective responses to physical activity offer potential mechanisms through which fatigability is increased in Veterans with post-COVID-19 fatigue. Moreover, home-based resistance exercise delivered remotely may provide a safe and feasibility treatment option for targeting neuromuscular and neurobehavioral factors influencing fatigability severity in this population.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Psychiatric Disorders, Cardiovascular, Musculoskeletal, Others

      52 Participants Needed

      Rehabilitation and Pacing for Long COVID

      Silver Spring, Maryland
      This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating interventions to address and improve exercise intolerance and post-exertional malaise (PEM) as manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The focus of this protocol is to assess interventions that can improve exercise capacity, daily activities tolerance, and quality of life in patients with PASC.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Active SARS-CoV-2, ME/CFS, Others

      660 Participants Needed

      Paxlovid for Long COVID

      Washington, District of Columbia
      This trial is testing various antiviral and other treatments to help people with long-term COVID-19 symptoms. The goal is to see if these treatments can get rid of any remaining virus, stop it from becoming active again, or calm down the immune system. Participants will receive different treatments to find out which works best.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      964 Participants Needed

      Cognitive Dysfunction Interventions for Long COVID

      Silver Spring, Maryland
      This trial is testing various treatments to help people who have thinking and attention problems after recovering from COVID-19. The goal is to find ways to improve these specific cognitive functions. A Ginkgo biloba extract has been suggested for treating cognitive post-COVID-19 symptoms due to its neuroprotective and anti-inflammatory properties.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      328 Participants Needed

      123

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Covid clinical trials pay?
      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
      How do Covid clinical trials work?
      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Covid trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Covid is 12 months.
      How do I participate in a study as a "healthy volunteer"?
      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
      What does the "phase" of a clinical trial mean?
      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
      Do I need to be insured to participate in a Covid medical study ?
      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
      What are the newest Covid clinical trials ?
      Most recently, we added PET Imaging for Post-COVID Syndrome, COVID-19 Therapeutic Biologic for COVID-19 and NE3107 for Post-COVID Syndrome to the Power online platform.